# A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

> **NCT02781311** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 169 (actual)

## Conditions studied

- Alopecia

## Interventions

- **DRUG:** Setipiprant
- **DRUG:** Placebo
- **DRUG:** Finasteride

## Key facts

- **NCT ID:** NCT02781311
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-14
- **Primary completion:** 2018-03-15
- **Final completion:** 2018-05-22
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2019-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781311, "A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT02781311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*